Last reviewed · How we verify
Trinity Health Of New England — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Arformoterol (Brovana) | Arformoterol (Brovana) | marketed | Long-acting beta-2 agonist (LABA) | Beta-2 adrenergic receptor | Respiratory |
Therapeutic area mix
- Respiratory · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AstraZeneca · 1 shared drug class
- Chiesi Farmaceutici S.p.A. · 1 shared drug class
- Dey · 1 shared drug class
- Fundacio Privada Mon Clinic Barcelona · 1 shared drug class
- Genentech, Inc. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Henan University of Traditional Chinese Medicine · 1 shared drug class
- Novartis · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Trinity Health Of New England:
- Trinity Health Of New England pipeline updates — RSS
- Trinity Health Of New England pipeline updates — Atom
- Trinity Health Of New England pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Trinity Health Of New England — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/trinity-health-of-new-england. Accessed 2026-05-17.